Celanese (CE) Announces Commercial Launch of Glaukos' iDose TR [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
The majority of glaucoma and ocular hypertension patients do not adhere to topical drug regimens due to complex dosing courses, adverse effects and eye-drop sensitivity. Sustained delivery of medications is a significant technique for addressing noncompliance and enhancing treatment results. With iDose TR and VitalDose EVA, it is now possible to give continuous dosing, which can increase patient compliance and alleviate adherence concerns. Food and Drug Administration (FDA) approved iDose TR in December 2023. It is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver therapeutic levels of a proprietary travoprost formulation inside the eye for extended periods of time. iDose TR was approved following the completion of two pivotal trials which demonstrated safety and efficacy. Glaukos used VitalDose EVA to develop a nanoporous membrane for travoprost administration in iDose TR. The VitalDose EVA is a platform that can
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos Announces the Release of its 2023 Sustainability Report [Yahoo! Finance]Yahoo! Finance
- Glaukos Announces the Release of its 2023 Sustainability ReportBusiness Wire
- Here's Why You Should Retain Glaukos (GKOS) Stock for Now [Yahoo! Finance]Yahoo! Finance
- Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally? [Yahoo! Finance]Yahoo! Finance
- Is Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)? [Yahoo! Finance]Yahoo! Finance
GKOS
Earnings
- 2/21/24 - Miss
GKOS
Sec Filings
- 4/16/24 - Form DEF
- 4/16/24 - Form ARS
- 4/16/24 - Form DEFA14A
- GKOS's page on the SEC website